Constellation Pharmaceuticals, Inc.
MARKERS FOR PERSONALIZED CANCER TREATMENT WITH LSD1 INHIBITORS
Last updated:
Abstract:
Provided herein are methods of treating cancers characterized by a high expression of GFIIB, comprising administering a therapeutically effective amount of a KDMIA inhibitor.
Status:
Application
Type:
Utility
Filling date:
8 Dec 2017
Issue date:
5 Mar 2020